Answers are grounded in this paper and cite their sources.
In a single-center trial, tDCS for the treatment of depression did not show noninferiority to escitalopram over a 10-week period and was associated with more adverse events. (Funded by Fundação de Amparo à Pesquisa do Estado de São Paulo and others; ELECT-TDCS ClinicalTrials.gov number, NCT01894815 .).
No takes yet. Share an insight, caveat, or question.
Brunoni et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: